1. 佐藤
秀蔵. 視覚毒性. 日薬理誌. 131, 50～54 (2008).
2. Gupta, M.P., et al. Retinal Anatomy and Pathology. Dev Ophthalmol. 55, 7-17 (2016).
3. Caspi, R.R. A look at autoimmunity and inflammation in the eye. J Clin Invest
.120, 3073-83 (2010).
4. Tripathy, K., et al. Serial ultra-wide field imaging for following up acute retinal
necrosis cases: Oman J Ophthalmol. 8, 71-2 (2015).
5. Schoenberger, S., et al. Diagnosis and Treatment of Acute Retinal Necrosis: A Report
by the American Academy of Ophthalmology. Ophthalmology. 124, 382-392 (2017).
6. Aurel, V.S. Experimentalle endogene infektionsttberstragung von Bulbus zu Bulbus.
Klin Monatsbl Augenheilkd. 72, 593-602 (1924).
7. Kimura, S.J. Herpes simplex uveitis: A clinical and experimental study. Trans Am
Ophthalmol Soc. 60, 440-470 (1962).
8. Pettit, T.H., et al: Herpes simplex uveitis : An experimental study with the
fluorescein-labeled antibody technique. Invest Ophthalmol Vis Sci. 4, 349-357(1965).
9. Whittum, J.A., et al: Ocular disease induced in mice by anterior chamber inoculation
of herpes simplex virus. Invest Ophthalmol Vis Sci. 25, 1065-1073 (1984).
10. 中川
尚. 実験的単純ヘルペス性網膜炎（von Szilyモデル）におけるウイ
76
ルス伝播経路について. 東女医大誌. 58, 671~676 (1988).
11. Labetoulle, M., et al: Neuronal pathways for the propagation of herpes simplex virus
type 1 from one retina to the other in a murine model. J Gen Virol. 81, 1201-10 (2000).
12. Pettit, H.T., et al: Herpes Simplex Uveitis: An Experimental Study with the
Fluorescein-labeled Antibody Technique. Invest Ophthalmol. 4, 349-57 (1965).
13. Jiang, Y. C., et al. New strategies against drug resistance to herpes simplex virus.
Int. J. Oral Sci. 8, 1–6 (2016).
14. Carninci, P., et al. The transcriptional landscape of the mammalian genome. Science.
309, 1559–1563 (2005).
15. Mizutani, R., et al. Identification and characterization of novel genotoxic stressinducible nuclear long noncoding RNAs in mammalian cells. PLoS One. 7, e34949
(2012).
16. Valadkhan, S., et al. LncRNAs in stress response. Curr. Top. Microbiol. Immunol.
394, 203–236 (2016).
17. Yilmaz, S.S., et al. Analysis of long non-coding RNA (lncRNA) expression in
hepatitis B patients. Bosn. J. Basic Med. Sci. 18, 150–161 (2018).
77
18. Huang, S., et al. The expression of lncRNA NEAT1 in human tuberculosis and its
antituberculosis effect. Biomed. Res. Int. 2018, 9529072 (2018).
19. Imamura, K., et al. Long non-coding RNAs involved in immune responses. Front.
Immunol. 5, 573 (2014).
20. Imamura, K., et al. Long noncoding RNA NEAT1-dependent SFPQ relocation from
promoter region to paraspeckle mediates IL8 expression upon immune stimuli. Mol.
Cell. 53, 393–406 (2014).
21. Imamura, K., et al. Diminished nuclear RNA decay upon Salmonella infection
upregulates antibacterial noncoding RNAs. EMBO J. 37, e97723 (2018).
22. Winterling, C., et al. Evidence for a crucial role of host non-coding RNA in
influenza A virus replication. RNA Biol. 11, 66–75 (2014).
23. Wang, J., et al. Influenza virus exploits an interferon-independent lncRNA to
preserve viral RNA synthesis through stabilizing viral RNA polymerase PB1. Cell Rep.
27, 3295–3304 (2019).
24. Wang, J., et al. Host long noncoding RNA lncRNA-PAAN regulates the replication
of influenza A virus. Viruses. 10, E330 (2018).
78
25. Wang, P., et al. An interferon-independent lncRNA promotes viral replication by
modulating cellular metabolism. Science. 358, 1051–1055 (2017).
26. Carnero, E., et al. Long noncoding RNA EGOT negatively affects the antivarial
response and favors HCV replication. EMBO Rep. 17, 1013–1028 (2016).
27. Imam, H., et al. The lncRNA NRON modulates HIV-1 replication in a NFATdependent manner and is differentially regulated by early and late viral proteins. Sci
Rep. 5, 8639 (2015).
28. Zhang, Q., et al. NEAT1 long noncoding RNA and paraspeckle bodies modulate
HIV-1 posttranscriptional expression. mBio. 4, e596–e512 (2013).
29. Qian, X., et al. Long non-coding RNA GAS5 inhibited hepatitis C virus replication
by binding viral NS3 protein. Virology. 492, 155-65 (2016).
30. Wang, Z., et al. NEAT1 modulates herpes simplex virus-1 replication by regulating
viral gene transcription. Cell Mol Life Sci. 74, 1117–1131 (2016).
31. Dana, H., et al. Molecular Mechanisms and Biological Functions of siRNA. Int J
Biomed Sci. 13, 48–57 (2017).
32. Valeur, E., et al. New Modalities for Challenging Targets in Drug Discovery. Angew
Chem Int Ed Engl. 56, 10294-10323 (2017).
79
33. Hickerson, P.R., et al. Stability Study of Unmodified siRNA and Relevance to Clinical
Use. Oligonucleotides. 18, 345–354 (2008).
34. Benizri, S., et al. Bioconjugated Oligonucleotides: Recent Developments and
Therapeutic Applications. Bioconjug Chem. 30, 366-383 (2019).
35. Guzman A.A., et al. Small-interfering RNAs (siRNAs) as a promising tool for
ocular therapy. Br. J. Pharmacol. 170, 730–747 (2013).
36. Kim, D., et al. HISAT: a fast spliced aligner with low memory requirements. Nat.
Methods. 12, 357–360 (2015).
37. Pertea, M., et al. StringTie enables improved reconstruction of a transcriptome from
RNA-seq reads. Nat. Biotechnol. 33, 290–295 (2015).
38. Pertea, M., et al. Transcript-level expression analysis of RNA-seq experiments with
HISAT, StringTie and Ballgown. Nat. Protoc. 11, 1650–1667 (2016).
39. Man, A., et al. The cyclin-dependent kinase 5 inhibitor peptide inhibits herpes
simplex virus type 1 replication. Sci. Rep. 9, 1260 (2019).
40. Roizman, B., et al. Whitley. Herpes simplex viruses, p. 2501-2602. In D. M. Knipe
and P. M. Howley (ed.), Virology, 5th ed. Lippincott-Williams &Wilkins, Philadelphia,
P.A. (2007).
80
41. Sandra, K., et al. Herpes Simplex Viruses: Mechanisms of DNA Replication. Cold
Spring Harb Perspect Biol. 4, a013011 (2012).
42. Roizman, B., et al. Herpes simplex viruses and their replication, p. 2399-2459. In P.
M. Howley and D. M. Knipe (ed.), Virology, 4th ed. Lippincott-Raven, Philadelphia, P.A.
(2001).
43. Sabikunnahar, S., et al. Functional characterization of a novel myeloid cell-specific
lncRNA U90926. J Immunol. 202, 187.26 (2019).
44. Chen, J., et al. The role and possible mechanism of lncRNA U90926 in modulating
3T3-L1 preadipocyte differentiation. Int. J. Obes. 41, 299–308 (2017).
45. Baron, S. Medical Microbiology 4th edition, Texas: University of Texas Medical
Branch at Galveston (1996).
46. 高岡
晃教、他. 自然免疫系における DNA センサー. ウイルス. 58, 37-46
(2008).
47. Lundin, K.E., et al. Oligonucleotide Therapies: The Past and the Present. Hum Gene
Ther. 26, 475-85 (2015).
48. Stein C.A., et al. FDA-Approved Oligonucleotide Therapies in 2017.
Mol Ther. 25, 1069-1075 (2017).
81
49. Adams, B. D., et al. Targeting noncoding RNAs in disease. J. Clin. Invest. 127, 761–
771 (2017).
50. Tatiparti, K., et al. siRNA delivery strategies: A comprehensive review of recent
developments. Nanomaterials (Basel). 7, E77 (2017).
51. Perry, C. M., et al. Fomivirsen. Drugs. 57, 375–380 (1999).
82
謝辞
研究の機会を与えて下さり、4 年間に渡り終始御懇意なる御指導、御鞭撻を賜
った東京大学大学院医学系研究科外科学専攻眼科学教室
相原
教授に心
より感謝申し上げます。
本研究の遂行にあたり、東京大学アイソトープ総合センター
教授、自治医科大学附属さいたま医療センター
学薬学部 裏出
良博
蕪城
俊克
教授、自治医科大学眼科学講座
京大学大学院医学系研究科外科学専攻眼科学教室
信佳
教授、第一薬科大
川島
田中
秋光
理恵
秀俊
教授、東
特任講師には
終始御懇意なる御指導、御鞭撻を賜り厚く感謝申し上げます。
共同研究を快く引き受けてくださった東京大学医科学研究所
ウイルス病態制御分野
加藤
哲久
助教、川口
感染・免疫部
教授に深謝致しま
す。
また本研究に際して数々の御助言、御協力を頂きました、東京大学アイソトー
プ総合センター 小野口（水谷） 玲菜
谷上 賢端
特任准教授、三木
敦子
特任助教、川田
健太郎
特任助教、
元特任助教をはじめ、秋光研究室の皆様
にこの場を借りて厚く御礼申し上げます。
83
...
論文の公開元へ
